|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Dyslipidemias | |||||
| 2 | More general conditions related to this trial | ||||
| Lipid Metabolism Disorders | |||||
| Metabolic Diseases | |||||
| 3 | Interventions listed in this trial | ||||
| 40 mg Pravastatin (Pravachol) | |||||
| 20 mg Simvastatin | |||||
| Placebo | |||||
| 4 | Additional drug interventions recognized in this trial | ||||
| Pravastatin | |||||
| Simvastatin | |||||
| 5 | More general drug interventions related to this trial | ||||
| Anticholesteremic Agents | |||||
| Antilipemic Agents | |||||
| Antimetabolites | |||||
| Enzyme Inhibitors | |||||
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Pharmacologic Actions | |||||
| Therapeutic Uses | |||||
| 6 | Sponsors listed in this trial | ||||
| National Heart, Lung, and Blood Institute (NHLBI) | |||||